Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

被引：13
|
作者：
Cohen, Ezra E. W.
Nabell, Lisle
Wong, Deborah J. L.
Day, Terry A.
Daniels, Gregory A.
Milhem, Mohammed M.
Deva, Sanjeev
Jameson, Michael B.
Guntinas-Lichius, Orlando
Almubarak, Mohammed
Strother, Robert Matthew
Whitman, Eric D.
Chisamore, Michael Jon
Obiozor, Cynthia Chinedu
Bagulho, Teresa
Candia, Albert
Gamelin, Erick
Janssen, Robert
Algazi, Alain Patrick
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
[5] Univ Iowa, Iowa City, IA USA
[6] Auckland City Hosp, Auckland, New Zealand
[7] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand
[8] Univ Hosp Jena, Head & Neck Surg, Jena, Germany
[9] West Virginia Univ, Morgantown, WV 26506 USA
[10] Christchurch Hosp, Canterbury Dist Hlth Board, Christchurch, New Zealand
[11] Atlantic Hlth Syst Canc Care, Morristown, NJ USA
[12] Merck & Co Inc, Rahway, NJ 07065 USA
[13] Dynavax Technol Corp, Berkeley, CA USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6039
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, E. E. W.
    Algazi, A.
    Laux, D.
    Wong, D. J.
    Amin, A.
    Nabell, L.
    Chisamore, M.
    Gamelin, E.
    Janssen, R.
    Bishnoi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 375 - 375
  • [2] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients
    Leung, Abraham C. F.
    Kummar, Shivaani
    Agarwala, Sanjiv S.
    Nemunaitis, John J.
    Gonzalez, Rene
    Drabick, Joseph J.
    Schmidt, Emmett V.
    Chartash, Elliot
    Xing, Biao
    Currie, Graeme
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Ribas, Antoni
    Milhem, Mohammed M.
    Hoimes, Christopher J.
    Amin, Asim
    Mehmi, Inderjit
    Lao, Christopher D.
    Conry, Robert Martin
    Shaheen, Montaser F.
    Jang, Sekwon
    Salama, April K. S.
    Deva, Sanjeev
    Medina, Theresa Michelle
    Schmidt, Emmett V.
    Leung, Abraham C. F.
    Xing, Biao
    Janssen, Robert
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy.
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Amin, Asim
    Lao, Christopher D.
    Conry, Robert Martin
    Hunt, Jason
    Daniels, Gregory A.
    Almubarak, Mohammed
    Shaheen, Montaser F.
    Medina, Theresa Michelle
    Barve, Minal A.
    Bishnoi, Sarwan K.
    Abdi, Ehtesham A.
    Chisamore, Michael Jon
    Xing, Biao
    Candia, Albert
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial
    Cohen, Ezra E. W.
    Nabell, Lisle
    Wong, Deborah J.
    Day, Terry
    Daniels, Gregory A.
    Milhem, Mohammed
    Deva, Sanjeev
    Jameson, Michael
    Guntinas-Lichius, Orlando
    Almubarak, Mohammed
    Strother, Matthew
    Whitman, Eric
    Chisamore, Michael
    Obiozor, Cynthia
    Bagulho, Teresa
    Gomez-Romo, Jose
    Guiducci, Cristiana
    Janssen, Robert
    Gamelin, Erick
    Algazi, Alain P.
    CLINICAL CANCER RESEARCH, 2022, 28 (06) : 1157 - 1166
  • [7] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
    Amin, Asim
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Medina, Theresa Michelle
    Conry, Robert Martin
    Lao, Christopher D.
    Daniels, Gregory A.
    Reddy, Sunil A.
    Andtbacka, Robert Hans Ingemar
    Barve, Minal A.
    Shaheen, Montaser F.
    Tueting, Thomas
    Chisamore, Michael Jon
    Schmidt, Emmett V.
    Candia, Albert
    Obiozor, Cynthia Chinedu
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Long, G. V.
    Milhem, M.
    Amin, A.
    Hoimes, C. J.
    Medina, T.
    Conry, R. M.
    Lao, C.
    Daniels, G.
    Reddy, S.
    Mehmi, I.
    Andtbacka, R. H. I.
    Barve, M.
    Shaheen, M.
    Tueting, T.
    Chisamore, M.
    Xing, B.
    Candia, A.
    Gamelin, E.
    Janssen, R.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF INCAGN01876 (ANTI-GITR AGONIST) IN COMBINATION WITH RETIFANLIMAB (ANTI-PD-1) IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Leidner, Rom
    Haddad, Robert
    Bourayou, Nawel
    Ioannidis, Sonia
    Zhou, Feng
    Dong, Zhiwan
    Cohen, Ezra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A707 - A707
12345